1 / 10

Bio-Reference Lab BRLI

Bio-Reference Lab BRLI. Andrew Tiffany. Company Overview. 3 rd largest full service lab in the U.S. Largest independent regional l ab in the northeastern market. National Oncology Lab Primarily a clinical testing lab Esoteric testing Molecular Diagnostics Anatomical Pathology .

lajos
Download Presentation

Bio-Reference Lab BRLI

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Bio-Reference Lab BRLI Andrew Tiffany

  2. Company Overview • 3rd largest full service lab in the U.S. • Largest independent regional lab in the northeastern market. • National Oncology Lab • Primarily a clinical testing lab • Esoteric testing • Molecular Diagnostics • Anatomical Pathology

  3. Current Holding • Purchase Price: $13.73 • Current Price: $21.70 • Shares Purchased: 100 • Current Shares: 150 • Sold 25 shares (10/27/09): $34.11 • Gain: 58.05% • Investment Gain: $1882 • Fair Value Estimate: $25.30

  4. Key Stats • P/E: 24.4 • Rev Growth (3yr Avg): 23.4 • EPS Growth (3yr Avg): 22.7 • Net Profit Margin: 5.8 • ROE: 19.2 • Debt/Equity: .1

  5. Compared to Industry BRLI Industry P/E: 31.5 P/B: 3.0 Rev Growth: 11.1 Operating Margin: 12.5% Net Profit Margin: .1% ROE: .1 Debt/Equity: 1.8 • P/E: 24.4 • P/B: 4.2 • Rev Growth: 23.4 • Operating Margin: 10.7% • Net Profit Margin: 5.8% • ROE: 19.2 • Debt/Equity: .1

  6. Performance 1 Year

  7. Performance 3 Month

  8. Current Events • 3Q profits rose 24% • 3Q revenue rose 25% • 3Q EPS: $0.29 (Expectations: $0.28) • Number of patients rose 17% • Revenue per patient rose 7% • Listed as one of 14 Stocks which are heavily shorted.

  9. Analysts Estimates/Recommendations • EPS: Current Year: .95 Next Year: 1.14 • Revenue: Current Year: 454.85 Mil Next Year: 524.65 Mil Number of Analysts: 12 Strong Buy: 1 Buy: 7 Hold: 4

  10. Recommendation • Since this stock has a lot of stocks being shorted and although this company has strong financials and has shown growth and will continue to grow. My recommendation is to sell this stock. Since they have reached their max high and since we have seen tremendous return on this stock I believe it is time to sell.

More Related